Retatrutide

Retatrutide is an investigational compound in Phase 3 clinical trials. It activates three separate hormone receptors at once (GLP-1, GIP, and glucagon), which is why early trials produced the largest weight losses and liver fat reductions ever recorded for a drug.

Key Benefits (from research) 

• Record weight loss in Phase 2 – A 48-week trial showed up to 24.2% average weight reduction; 100% of participants at the highest dose lost at least 5%.

• Dramatic liver fat reduction — A Phase 2a liver sub-study showed up to 82.4% relative reduction in liver fat; 93% of participants reached a normal liver fat level

• Reduces blood sugar — Phase 1 and meta-analysis data confirm significant HbA1c and fasting glucose reductions in people with type 2 diabetes.

• Improves cardiovascular risk factors – Significant improvements in blood pressure, triglycerides, LDL cholesterol, and waist circumference documented across trials.

• Phase 3 TRIUMPH programme under way – Ongoing trials cover weight management, sleep apnoea, knee osteoarthritis, and fatty liver disease.

• Burns fat through thermogenesis – The glucagon component increases heat production in fat cells and the liver, adding an energy-expenditure effect on top of appetite control.

Quick Q&A 

What is Retatrutide used for in research? 

It is studied as a triple-receptor compound for weight loss, liver fat reduction, blood sugar control, and cardiovascular risk.

Is it approved for people? 

No — it is in Phase 3 clinical development and not yet approved. The compound sold here is for laboratory research only.

More information about Retatrutide

Retatrutide (LY3437943) is a next-generation triple agonist of the GLP-1, GIP, and glucagon receptors. By simultaneously engaging all three incretin-related pathways, it has demonstrated the most pronounced weight reduction and metabolic effects in early-phase clinical research to date. A frontier compound in obesity and metabolic disease research. For laboratory research use only.